Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Staidson (Beijing) Biopharmaceuticals Co ROA % Related Terms
Staidson (Beijing) Biopharmaceuticals Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staidson (Beijing) Biopharmaceuticals Co ROA % Chart
Staidson (Beijing) Biopharmaceuticals Co Annual Data
For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staidson (Beijing) Biopharmaceuticals Co ROA % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) has a ROA % of -8.77% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #396 out of 1413 companies in the Biotechnology industry, placing it in the top 28%.
Is Staidson (Beijing) Biopharmaceuticals Co's ROA % too high?
Staidson (Beijing) Biopharmaceuticals Co's current ROA % is -8.77%. Based on the distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #396 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Staidson (Beijing) Biopharmaceuticals Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Staidson (Beijing) Biopharmaceuticals Co's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #396 out of 1413 companies for ROA %. This puts Staidson (Beijing) Biopharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. Staidson (Beijing) Biopharmaceuticals Co's current ROA % is -8.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staidson (Beijing) Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.34, compared to a current price of ¥20.94 — trading 382.5% above its estimated fair value. The current ROA % is -8.77%. Staidson (Beijing) Biopharmaceuticals Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204), the current ROA % is -8.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Overvalued in 2026?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥20.94 is trading 382.5% above its estimated GF Value™ of ¥4.34.
GuruFocus considers Staidson (Beijing) Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for SZSE:300204:
ROA %: -8.77%
GF Value™: ¥4.34 vs. price of ¥20.94 (382.5% above fair value)
No single metric tells the full story. See the SZSE:300204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
46GF Score
Get the complete analysis for SZSE:300204
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300204 has been successfully added to your 
